E3 PreliminaryPreliminaryPEM unclearReview-NarrativePeer-reviewedMachine draft
Current update on the neurological manifestations of long COVID: more questions than answers.
Stefanou, Maria-Ioanna, Panagiotopoulos, Evangelos, Palaiodimou, Lina et al. · EXCLI journal · 2024 · DOI
Quick Summary
This review examines the nerve and brain-related symptoms that can persist after COVID-19 infection, which doctors call long COVID. About one-third of COVID-19 survivors experience lasting neurological problems such as fatigue, brain fog, sleep issues, and problems with smell or taste that can last at least 12 months. The authors discuss what we currently know about why these symptoms happen and what treatments might help.
Why It Matters
This comprehensive review is highly relevant to ME/CFS because long COVID and ME/CFS share numerous overlapping symptoms and potentially similar pathophysiological mechanisms (neuroinflammation, metabolic dysfunction, post-exertional malaise). Understanding long COVID's neurological manifestations may illuminate shared disease pathways and inform more effective diagnostic and therapeutic strategies that benefit both patient populations. The emphasis on multimodal, rehabilitation-based approaches aligns with evidence-based ME/CFS management principles.
Observed Findings
- Approximately one-third of COVID-19 survivors experience neurological sequelae persisting ≥12 months post-infection.
- Core neurological manifestations include fatigue, post-exertional malaise, cognitive impairment, headache, brain fog, sleep disturbance, taste/smell disorders, dysautonomia, anxiety, and depression.
- Data-driven approaches using electronic health records, machine learning, and artificial intelligence have identified distinct long COVID sub-phenotypes.
- Neuroinflammatory responses, endotheliopathy, and metabolic imbalances are implicated as primary mechanisms rather than direct viral brain invasion.
- Vaccination has demonstrated benefit in reducing long COVID incidence.
Inferred Conclusions
- Long COVID neurological manifestations represent a complex, heterogeneous condition requiring standardized diagnostic definitions and collaborative international efforts.
- Multimodal treatment approaches integrating pharmacological, non-pharmacological, and comprehensive rehabilitation interventions are needed.
- Genetic susceptibility and immune dysregulation (rather than persistent viral infection) likely drive neurological sequelae in long COVID.
- Further research is needed to clarify underlying pathophysiology and establish robust therapeutic efficacy before generalizing trial findings to broader populations.
What This Study Does Not Prove
As a narrative review rather than a primary research study, this does not provide new empirical data or definitive proof of causation for long COVID's neurological symptoms. The review acknowledges that pathophysiological mechanisms remain incompletely elucidated and that existing therapeutic evidence is preliminary with significant methodological limitations. The substantial phenotypic overlap with ME/CFS does not establish whether these are related conditions or distinct diseases.
Tags
Symptom:Post-Exertional MalaiseCognitive DysfunctionUnrefreshing SleepOrthostatic IntoleranceFatigueSensory Sensitivity
Biomarker:CytokinesMetabolomicsAutoantibodiesNeuroimaging
Phenotype:Infection-TriggeredLong COVID Overlap
Method Flag:Weak Case DefinitionExploratory Only
Metadata
- DOI
- 10.17179/excli2024-7885
- PMID
- 39850323
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 10 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →